Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.
Rizzoli, R.; Akesson, K.; Bouxsein, M.et al.
2011 • In Osteoporosis International, 22, p. 373-390
[en] This paper reviews the evidence for an association between atypical subtrochanteric fractures and long-term bisphosphonate use. Clinical case reports/reviews and case-control studies report this association, but retrospective phase III trial analyses show no increased risk. Bisphosphonate use may be associated with atypical subtrochanteric fractures, but the case is yet unproven. INTRODUCTION: A Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the International Osteoporosis Foundation has reviewed the evidence for a causal association between subtrochanteric fractures and long-term treatment with bisphosphonates, with the aim of identifying areas for further research and providing recommendations for physicians. METHODS: A PubMed search of literature from 1994 to May 2010 was performed using key search terms, and articles pertinent to subtrochanteric fractures following bisphosphonate use were analysed. RESULTS: Several clinical case reports and case reviews report a possible association between atypical fractures at the subtrochanteric region of the femur in bisphosphonate-treated patients. Common features of these 'atypical' fractures include prodromal pain, occurrence with minimal/no trauma, a thickened diaphyseal cortex and transverse fracture pattern. Some small case-control studies report the same association, but a large register-based study and retrospective analyses of phase III trials of bisphosphonates do not show an increased risk of subtrochanteric fractures with bisphosphonate use. The number of atypical subtrochanteric fractures in association with bisphosphonates is an estimated one per 1,000 per year. It is recommended that physicians remain vigilant in assessing their patients treated with bisphosphonates for the treatment or prevention of osteoporosis and advise patients of the potential risks. CONCLUSIONS: Bisphosphonate use may be associated with atypical subtrochanteric fractures, but the case is unproven and requires further research. Were the case to be proven, the risk-benefit ratio still remains favourable for use of bisphosphonates to prevent fractures.
Disciplines :
General & internal medicine
Author, co-author :
Rizzoli, R.
Akesson, K.
Bouxsein, M.
Kanis, J. A.
Napoli, N.
Papapoulos, S.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Cooper, C.
Language :
English
Title :
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.
Publication date :
2011
Journal title :
Osteoporosis International
ISSN :
0937-941X
eISSN :
1433-2965
Publisher :
Springer Science & Business Media B.V., Godalming, United Kingdom
DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541 1:CAS:528:DyaK2sXisFCktQ%3D%3D 10.1016/S0140-6736(96)07088-2 8950879
DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2927 2938 1:CAS:528:DC%2BD2sXnvVGh 10.1001/jama.296.24.2927 17190893
DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D 10.1056/NEJMoa067312 17476007
CH Chesnut III A Skag C Christiansen R Recker JA Stakkestad A Hoiseth D Felsenberg H Huss J Gilbride RC Schimmer PD Delmas 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249 1:CAS:528: DC%2BD2cXntFGqurw%3D 10.1359/JBMR.040325
SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082 1:CAS:528:DyaK1MXjsVWruw%3D%3D 10.1001/jama.280.24.2077 9875874
ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut III J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10.1001/jama.282.14.1344 10527181
KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 1:CAS:528:DC%2BD2sXht1Kit7nN 10.1056/NEJMoa074941 17878149
J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10.1007/s001980050010 10663363
OH Sorensen GM Crawford H Mulder DJ Hosking C Gennari D Mellstrom S Pack D Wenderoth C Cooper JY Reginster 2003 Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 120 126 1:CAS:528:DC%2BD3sXhvFWqu7o%3D 10.1016/S8756-3282(02)00946-8 12633783
MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier JY Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333 340 1:CAS:528:DC%2BD3MXht1Wlu7g%3D 10.1056/NEJM200102013440503 11172164
DM Reid JP Devogelaer K Saag C Roux CS Lau JY Reginster P Papanastasiou A Ferreira F Hartl T Fashola P Mesenbrink PN Sambrook 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 373 1253 1263 1:CAS:528:DC%2BD1MXktlyqtb4%3D 10.1016/S0140-6736(09)60250-6 19362675
JP Devogelaer 2002 Modern therapy for Paget's disease of bone: focus on bisphosphonates Treat Endocrinol 1 241 257 1:CAS:528:DC%2BD38Xnt1WisL0%3D 10.2165/00024677-200201040-00006 15799218
A Lipton 2007 Treatment of bone metastases and bone pain with bisphosphonates Support Cancer Ther 4 92 100 1:CAS:528:DC%2BD2sXktFKqtLo%3D 10.3816/SCT.2007.n.003 18632473
TJ Polascik 2009 Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases Drug Des Devel Ther 3 27 40 1:CAS:528:DC%2BD1MXoslSmsLk%3D 19920919
US Food and Drug Administration (FDA) (2009) Drug safety newsletter. Volume 2, Number 2. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ default.htm. Accessed 23 Sep 2010
JP Bilezikian 2006 Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med 355 2278 2281 1:CAS:528:DC%2BD28Xht1yitLzM 10.1056/NEJMp068157 17135582
R Rizzoli N Burlet D Cahall PD Delmas EF Eriksen D Felsenberg J Grbic M Jontell R Landesberg A Laslop M Wollenhaupt S Papapoulos O Sezer M Sprafka JY Reginster 2008 Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis Bone 42 841 847 1:CAS:528:DC%2BD1cXkvVOqsbs%3D 10.1016/j.bone.2008. 01.003 18314405
N Guanabens P Peris A Monegal F Pons A Collado J Munoz-Gomez 1994 Lower extremity stress fractures during intermittent cyclical etidronate treatment for osteoporosis Calcif Tissue Int 54 431 434 1:STN:280:DyaK2czktVCksA%3D%3D 10.1007/BF00305532 7914822
R Armamento-Villareal N Napoli K Diemer M Watkins R Civitelli S Teitelbaum D Novack 2009 Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series Calcif Tissue Int 85 37 44 1:CAS:528:DC%2BD1MXosVGrtL4%3D 10.1007/s00223-009-9263-5 19548019
SK Goh KY Yang JS Koh MK Wong SY Chua DT Chua TS Howe 2007 Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution J Bone Joint Surg Br 89 349 353 10.1302/0301-620X.89B3.18146 17356148
K Ing-Lorenzini J Desmeules O Plachta D Suva P Dayer R Peter 2009 Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital Drug Saf 32 775 785 1:CAS:528:DC%2BD1MXht1WhsbjL 10.2165/00002018-200932090-00002 19670917
EB Kwek SK Goh JS Koh MA Png TS Howe 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39 224 231 10.1016/j.injury.2007.08.036 18222447
BA Lenart AS Neviaser S Lyman CC Chang F Edobor-Osula B Steele MC van der Meulen DG Lorich JM Lane 2009 Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study Osteoporos Int 20 1353 1362 1:CAS:528:DC%2BD1MXotlyhurY%3D 10.1007/s00198-008-0805-x 19066707
AS Neviaser JM Lane BA Lenart F Edobor-Osula DG Lorich 2008 Low-energy femoral shaft fractures associated with alendronate use J Orthop Trauma 22 346 350 10.1097/BOT.0b013e318172841c 18448990
CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301 1:CAS:528:DC%2BD2MXisVOhsr0%3D 10.1210/jc.2004-0952 15598694
Muller ME, Nazarian S, Koch P, Schatzker J (1990) The AO classification of long bones. http://aofoundation.com/AOFileServer/PortalFiles?FilePath=/ Extranet/en/-att/wor/act/fracture-classif/mueller-ao-class.pdf. Accessed 23 Sep 2010
F Seinsheimer 1978 Subtrochanteric fractures of the femur J Bone Joint Surg Am 60 300 306 1:STN:280:DyaE1c7ntFKjsw%3D%3D 649632
Black DM, Genant HK, Bucci-Rechtweg C, Bauer DC, Mesenbrink PG, Palermo L, Nusgarten L, Eastell R (2009) Does zoledronic acid increase risk of atypical subtrochanteric femoral shaft fractures? Results from the HORIZON-PFT. J Bone Miner Res 24 (Suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/ AbstractDetail.aspx?aid=918d35dd-6a3d-43f6-b35f-b484a15b81cf. Accessed 23 Sep 2010
RD Bunning RJ Rentfro JS Jelinek 2010 Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series PM&R 2 76 80 10.1016/j.pmrj.2009.11.007
CM Capeci NC Tejwani 2009 Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy J Bone Joint Surg Am 91 2556 2561 10.2106/JBJS.H.01774 19884427
JS Koh SK Goh MA Png EB Kwek TS Howe 2010 Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 24 75 81 10.1097/BOT.0b013e3181b6499b 20101130
M Visekruna D Wilson FE McKiernan 2008 Severely suppressed bone turnover and atypical skeletal fragility J Clin Endocrinol Metab 93 2948 2952 1:CAS:528:DC%2BD1cXpvVOmurg%3D 10.1210/jc.2007-2803 18522980
EB Kwek JS Koh TS Howe 2008 More on atypical fractures of the femoral diaphysis N Engl J Med 359 316 317 1:CAS:528:DC%2BD1cXoslGitLw%3D 10.1056/NEJMc080861 18635442
BA Lenart DG Lorich JM Lane 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate N Engl J Med 358 1304 1306 1:CAS:528:DC%2BD1cXjvVarsb8%3D 10.1056/NEJMc0707493 18354114
F Leung T-W Lau M To K-K Luk A Kung 2010 Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates BMJ Case Reports 10.1136/bcr.10.2008.1073
EA Brandser JA Buckwalter 1996 Imaging studies for diagnosing stress and insufficiency fractures Iowa Orthop J 16 70 78 1:STN:280:DyaK2s3nsFequw%3D%3D 9129276
K Lunsjo L Ceder J Tidermark P Hamberg BE Larsson B Ragnarsson RW Knebel I Allvin K Hjalmars S Norberg P Fornander A Hauggaard L Stigsson 1999 Extramedullary fixation of 107 subtrochanteric fractures: a randomized multicenter trial of the Medoff sliding plate versus 3 other screw-plate systems Acta Orthop Scand 70 459 466 1:STN:280:DC%2BD3c%2Fos1Wqsg%3D%3D 10.3109/17453679909000981 10622478
GP Whitelaw D Segal CF Sanzone NS Ober N Hadley 1990 Unstable intertrochanteric/subtrochanteric fractures of the femur Clin Orthop Relat Res 252 238 245 2302890
JW Nieves JP Bilezikian JM Lane TA Einhorn Y Wang M Steinbuch F Cosman 2010 Fragility fractures of the hip and femur: incidence and patient characteristics Osteoporos Int 21 299 408 10.1007/s00198-009-0962-6
DA Glennon 2009 Subtrochanteric stress fractures in six patients on long term bisphosphonate therapy: a case series Bone 44 S68 S98 10.1016/j.bone.2009. 01.172
National Institute for Health and Clinical Excellence (2010) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE technology appraisal guidance 160 (amended). http://www.nice.org.uk/nicemedia/pdf/TA160guidance.pdf. Accessed 23 Sep 2010
O Johnell JA Kanis 2006 An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 1726 1733 1:STN:280:DC%2BD28nitVSksQ%3D%3D 10.1007/s00198-006-0172-4 16983459
A Giusti NA Hamdy SE Papapoulos 2010 Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies Bone 47 169 180 1:CAS:528:DC%2BC3cXos1Chu70%3D 10.1016/j.bone.2010.05.019 20493982
G Husada K Libberecht T Peeters J Populaire 2005 Bilateral mid-diaphyseal femoral stress fractures in the elderly Eur J Trauma 31 68 71 10.1007/s00068-005-1421-5
JP Schneider 2006 Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate Geriatrics 61 31 33 16405362
R Armamento-Villareal N Napoli V Panwar D Novack 2006 Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis N Engl J Med 355 2048 2050 1:CAS:528:DC%2BD28XhtFymurbI 10.1056/NEJMc062268 17093260
RK Cheung KK Leung KC Lee TC Chow 2007 Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate Hong Kong Med J 13 485 489 18057440
B Demiralp S Ilgan KA Ozgur EI Cicek D Yildrim K Erler 2007 Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: a case report Arch Orthop Trauma Surg 127 597 601 10.1007/s00402-007-0373-0 17572902
P Lee H van der Wall MJ Seibel 2007 Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy J Endocrinol Investig 30 590 597 1:CAS:528:DC%2BD2sXht1yktrzF
AS Sayed-Noor GO Sjoden 2008 Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy-a case report Acta Orthop 79 565 567 10.1080/17453670710015580 18766492
CV Odvina S Levy S Rao JE Zerwekh RD Sudhaker 2009 Unusual mid-shaft fractures during long term bisphosphonate therapy Clin Endocrinol (Oxf) 72 161 168 10.1111/j.1365-2265.2009.03581.x
T Ali RH Jay 2009 Spontaneous femoral shaft fracture after long-term alendronate Age Ageing 38 625 626 10.1093/ageing/afp106 19556326
MS Goddard KR Reid JC Johnston HS Khanuja 2009 Atraumatic bilateral femur fracture in long-term bisphosphonate use Orthopedics 32 607 10.3928/01477447-20090624-27 10.3928/01477447-20090624-27
AS Sayed-Noor GO Sjoden 2009 Case reports: two femoral insufficiency fractures after long-term alendronate therapy Clin Orthop Relat Res 467 1921 1926 10.1007/s11999-009-0725-x 19198962
K Cermak F Shumelinsky J Alexiou MJ Gebhart 2009 Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy Clin Orthop Relat Res 468 1991 1996 10.1007/s11999-009-1192-0 20020334
Bush LA, Chew FS (2009) Subtrochanteric femoral insufficiency fracture in woman on bisphosphonate therapy for glucocorticoid-induced osteoporosis. Radiol Case Rep 4. doi: 1.2484/rcr.v4i1.261
JK Lee 2009 Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium Int J Rheum Dis 12 149 154 10.1111/j.1756-185X. 2009.01396.x 20374333
MH Edwards FC McCrae SA Young-Min 2010 Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int 21 701 703 1:STN:280:DC%2BC3c7ls1ynuw%3D%3D 10.1007/s00198-009-0986-y 19562241
J Schilcher P Aspenberg 2009 Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate Acta Orthop 80 413 415 10.3109/17453670903139914 19568963
B Abrahamsen P Eiken R Eastell 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study J Bone Miner Res 24 1095 1102 1:CAS:528:DC%2BD1MXmvFyjtrY%3D 10.1359/jbmr.081247 19113931
DM Black DE Thompson DC Bauer K Ensrud T Musliner MC Hochberg MC Nevitt S Suryawanshi SR Cummings 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118 4124 1:CAS:528:DC%2BD3cXotlWnurw%3D 10.1210/jc.85.11.4118 11095442
DM Black MP Kelly HK Genant L Palermo R Eastell C Bucci-Rechtweg J Cauley PC Leung S Boonen A Santora A de Papp DC Bauer 2010 Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N Engl J Med 362 1761 1771 1:CAS:528:DC%2BC3cXmtVSrsr4%3D 10.1056/NEJMoa1001086 20335571
Bilezikian J, Klemes A, Silverman S, Cosman F (2009) Subtrochanteric fracture reports coincident with risedronate use. J Bone Miner Res 24(Suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= 0367cfaa-4d0d-47d8-a57a-ff76098839a2. Accessed 23 Sep 2010
JA Eisman R Civitelli S Adami E Czerwinski C Recknor R Prince JY Reginster M Zaidi D Felsenberg C Hughes N Mairon D Masanauskaite DM Reid PD Delmas RR Recker 2008 Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study J Rheumatol 35 488 497 1:CAS:528:DC%2BD1cXksFKjtrY%3D 18260172
PD Miller MR McClung L Macovei JA Stakkestad M Luckey B Bonvoisin JY Reginster RR Recker C Hughes EM Lewiecki D Felsenberg PD Delmas DL Kendler MA Bolognese N Mairon C Cooper 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res 20 1315 1322 1:CAS:528:DC%2BD2MXovV2msrk%3D 10.1359/JBMR.050313 16007327
R Recker JA Stakkestad CH Chesnut III C Christiansen A Skag A Hoiseth M Ettinger P Mahoney RC Schimmer PD Delmas 2004 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis Bone 34 890 899 1:CAS:528:DC%2BD2cXjs1WktrY%3D 10.1016/j.bone.2004.01.008 15121021
PD Miller S Epstein F Sedarati JY Reginster 2008 Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study Curr Med Res Opin 24 207 213 1:CAS:528:DC%2BD1cXhvVOgtL8%3D 18042311
JA Stakkestad P Lakatos R Lorenc F Sedarati C Neate JY Reginster 2008 Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension Clin Rheumatol 27 955 960 10.1007/s10067-007-0824-6 18180976
MR McClung MA Bolognese F Sedarati RR Recker PD Miller 2009 Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss Bone 44 418 422 1:CAS:528:DC%2BD1MXhvF2qsb4%3D 10.1016/j.bone.2008.09.011 18950736
G Bianchi D Felsenberg E Czerwinski D Reid A Kenwright A Burdeska R Recker 2009 Efficacy of IV ibandronate is maintained over 5 years: the DIVA LTE study Ann Rheum Dis 68 Suppl 3 494
European Medicines Agency (2009) Assessment report for Fosavance. EMEA/CHMP/188952/2009. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Assessment-Report-Variation/human/000619/WC500024252.pdf. Accessed 23 Sep 2010
European Medicines Agency (2009) EMEA 2010 priorities for drug safety research. Long-term adverse skeletal effects of bisphosphonates. Doc.Ref: EMEA/493711/2009 Rev.1. European Medicines Agency, London
US Food and Drug Administration (FDA) (2010) FDA drug safety communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric fractures. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm. Accessed 23 Sep 2010
E Durchschlag EP Paschalis R Zoehrer P Roschger P Fratzl R Recker R Phipps K Klaushofer 2006 Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate J Bone Miner Res 21 1581 1590 1:CAS:528:DC%2BD28XhtFekt7zI 10.1359/jbmr.060701 16995813
AL Boskey L Spevak RS Weinstein 2009 Spectroscopic markers of bone quality in alendronate treated postmenopausal women Osteoporos Int 20 793 800 1:CAS:528:DC%2BD1MXjvFaqtrs%3D 10.1007/s00198-008-0725-9 18769963
Turner CH, Burr DB (2006) Principles of bone biomechanics. In: Lane NE, Sambrook PN (eds) Osteoporosis and the osteoporosis of rheumatic diseases. Mosby Elsevier, Philadelphia, pp 41-53
GY Boivin PM Chavassieux AC Santora J Yates PJ Meunier 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women Bone 27 687 694 1:CAS:528:DC%2BD3cXosFygtL8%3D 10.1016/S8756-3282(00)00376-8 11062357
P Roschger S Rinnerthaler J Yates GA Rodan P Fratzl K Klaushofer 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women Bone 29 185 191 1:CAS:528:DC%2BD3MXlvFWkurk%3D 10.1016/S8756-3282(01)00485-9 11502482
MR Allen DB Burr 2007 Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment J Bone Miner Res 22 1759 1765 1:CAS:528:DC%2BD2sXhtlGqsL7I 10.1359/jbmr.070720 17663638
MR Allen K Iwata R Phipps DB Burr 2006 Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate Bone 39 872 879 1:CAS:528:DC%2BD28XpsVOhurY%3D 10.1016/j.bone.2006.04.028 16765660
MR Allen S Reinwald DB Burr 2008 Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment Calcif Tissue Int 82 354 360 1:CAS:528: DC%2BD1cXnsVCmsb8%3D 10.1007/s00223-008-9131-8 18463913
K Iwata MR Allen R Phipps DB Burr 2006 Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than with risedronate Bone 38 Suppl 42 10.1016/j.bone.2005.12.023
Y Cao S Mori T Mashiba MS Westmore L Ma M Sato T Akiyama L Shi S Komatsubara K Miyamoto H Norimatsu 2002 Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats J Bone Miner Res 17 2237 2246 1:CAS:528:DC%2BD38XpsV2lsb4%3D 10.1359/jbmr.2002.17. 12.2237 12469918
MM MacDonald A Schindeler DG Little 2007 Bisphosphonate treatment and fracture repair BoneKey 4 236 251
MD Martinez GJ Schmid JA McKenzie DM Ornitz MJ Silva 2010 Healing of non-displaced fractures produced by fatigue loading of the mouse ulna Bone 46 1604 1612 10.1016/j.bone.2010.02.030 20215063
MP Somford FW Draijer BJ Thomassen PM Chavassieux G Boivin SE Papapoulos 2009 Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility J Bone Miner Res 24 1736 1740 10.1359/jbmr.090408 19419297
TW O'Neill 2005 Looking back: developments in our understanding of the occurrence, aetiology and prognosis of osteoporosis over the last 50 years Rheumatology (Oxford) 44 iv33 iv35 10.1093/rheumatology/kei059
JA Kanis EV McCloskey H Johansson O Strom F Borgstrom A Oden 2008 Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK Osteoporos Int 19 1395 1408 1:STN:280: DC%2BD1crnvFelug%3D%3D 10.1007/s00198-008-0712-1 18751937
JA Kanis F Borgstrom N Zethraeus O Johnell A Oden B Jonsson 2005 Intervention thresholds for osteoporosis in the UK Bone 36 22 32 10.1016/j.bone.2004.08.018 15663999
